Recombinant Human Erythropoietin and Haemodialyser Re-Use
نویسندگان
چکیده
منابع مشابه
Safe and efficacious use of recombinant human erythropoietin in malignancy.
Recombinant human erythropoietic proteins (rhEpo) can be used in anaemic patients with malignancy receiving chemotherapy to reduce transfusion requirements and improve quality of life. It is highly efficacious when used with appropriate intravenous (iv) iron supplementation to combat functional iron deficiency. There is no indication that rhEpo improves either survival or the outcome of treatme...
متن کاملUse of Cuban recombinant human erythropoietin in Parkinson's disease treatment.
INTRODUCTION Recombinant human erythropoietin is used primarily to treat anemia. There is evidence of its neuroprotective capacity from preclinical studies in Parkinson's disease and other neurodegenerative diseases. Recombinant human erythropoietin produced in Cuba (ior-EPOCIM) is registered and approved for use in humans in Cuba and in a number of other countries. OBJECTIVE Assess safety an...
متن کاملNononcologic use of human recombinant erythropoietin therapy in hospitalized patients.
BACKGROUND Human recombinant erythropoietin (rHuEPO) is widely used to stimulate red blood cell production in patients with anemia due to cancer, renal disease, and other medical conditions, but concern has grown about its overuse and potential for harm. Little is known about the nature of rHuEPO use in hospitalized patients who receive rHuEPO therapy for nononcologic indications. METHODS We ...
متن کاملGuidelines for the use of recombinant human erythropoietin.
ecombinant human erythropoietin (rHuEpo) is increasingly being used for the treatment of anemia. In view of the unpredictibility of response in most anemic states outside renal failure, the high economic cost, and the high expectation patients and physicians pose in its effect, its clinical use requires expertise and committment. This article was prepared by five experts: four on behalf of the ...
متن کاملUse of recombinant human erythropoietin outside the setting of uremia.
R concentration. Abnormally high Epo levels have been reported in patients with aplastic anemia, and dramatic ECOMBINANT human erythropoietin (rHuEpo) became available for clinical trials in 1985 and was introduced into clinical practice for correction of anemia of renal changes in serum levels have been described after chemotherapy and during vitamin B12 or iron replacement therfailure in 1989...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nephron
سال: 1990
ISSN: 1660-8151,2235-3186
DOI: 10.1159/000186195